Concord Biotech Announces 1:1 Bonus Issue; Record Date Yet To Be Fixed
Add Preferred News Source
Concord Biotech’s stock has gained nearly 51% in six months. The company has now approved its first-ever 1:1 bonus issue, with 10.46 crore shares to be issued.
Concord Biotech Limited has approved its first-ever 1:1 bonus issue, with the board clearing the proposal on 23 September 2026. Under the issue, shareholders will receive one bonus equity share of ₹1 each for every one fully paid-up equity share held on the record date.
The company is also backed by the Jhunjhunwala family. Three Jhunjhunwala family discretionary trusts hold 8% each in Concord Biotech as of 23 September.
The Concord Biotech share price closed 1.82% higher at ₹1,560.30 on the National Stock Exchange (NSE) on 23 September. The stock has gained around 50.8% over the past six months and about 16.6% so far in 2026.
What Is The Concord Biotech Bonus Issue Ratio?
The company will issue 10,46,16,204 bonus equity shares of ₹1 each, amounting to ₹10.46 crore. The bonus will be funded by capitalising the company's share premium account.
Concord Biotech has said that ₹81.97 crore was available in its share premium account as of 31 March 2026, while ₹10.46 crore will be required for the bonus issue.
The company's paid-up share capital will consequently increase from ₹10.46 crore, divided into 10.46 crore shares, to ₹20.92 crore, divided into 20.92 crore shares.
When Is The Concord Biotech Bonus Issue Record Date?
The Concord Biotech bonus issue record date has not been announced yet. The board will determine the date separately to establish which shareholders will be eligible for the bonus shares.
The company expects the bonus shares to be credited or dispatched within two months from the board meeting approving the bonus issue, which means the estimated timeline is by 22 November 2026.
The bonus issue remains subject to shareholder approval.
Why Is Concord Biotech Increasing Its Authorised Share Capital?
Alongside the bonus issue, the board approved an increase in the authorised share capital from ₹11 crore to ₹22 crore.
This will raise the authorised number of equity shares from 11 crore to 22 crore shares, with the additional 11 crore shares carrying a face value of ₹1 each. The change is also subject to shareholder approval.
Also Read - Airtel Money IPO: Mobile Money Arm Targets Up To US$9 Billion Valuation In London
This article is for informational purposes only and should not be considered investment advice from Kotak Neo. For compliance T&C and disclaimers, Visit www.kotakneo.com/disclaimer
Vishwa has spent 10+ years across fintech and FMCG doing what most people miss, connecting the dots, catching trends before they trend, and finding the angle nobody else thought to ask about.
At Kotak Neo, she drives content strategy for neoshorts, Kotak News Desk, and Investing Guide, turning market noise into something worth reading.
When she's not decoding markets, she trades charts for canvases, chasing art, painting, and architecture across cities she's yet to explore.
Right Tools, Rich Insights
